✦ LIBER ✦

O166 ALL-ORAL DUAL THERAPY WITH DACLATASVIR AND ASUNAPREVIR IN PATIENTS WITH HCV GENOTYPE 1B INFECTION: PHASE 3 STUDY RESULTS

✍ Scribed by Manns, M.; Pol, S.; Jacobson, I.; Marcellin, P.; Gordon, S.; Peng, C.-Y.; Chang, T.-T.; Everson, G.; Heo, J.; Gerken, G.; Yoffe, B.; Towner, W.J.; Bourliere, M.; Metivier, S.; Chu, C.-J.; Sievert, W.; Bronowicki, J.-P.; Thabut, D.; Lee, Y.-J.; Kao, J.-H.; McPhee, F.; Kopit, J.; Mendez, P.; Linaberry, M.; Hughes, E.; Noviello, S.

Book ID: 122257037
Publisher: Elsevier Science
Year: 2014
Tongue: English
Weight: 120 KB
Volume: 60
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(14)61461-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Dual oral therapy with daclatasvir and a

Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options

✍ Suzuki, Yoshiyuki; Ikeda, Kenji; Suzuki, Fumitaka; Toyota, Joji; Karino, Yoshiya 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 941 KB

763 All-Oral Therapy With Daclatasvir in

763 All-Oral Therapy With Daclatasvir in Combination With Asunaprevir and Bms-791325 for Treatment-Naive Patients With Chronic HCV Genotype 4 Infection

✍ Hassanein, Tarek; Everson, Gregory T.; Sims, Karen; Bennett, Michael T.; Gitlin, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 166 KB

P1163 ALL-ORAL THERAPY WITH DACLATASVIR

P1163 ALL-ORAL THERAPY WITH DACLATASVIR IN COMBINATION WITH ASUNAPREVIR AND BMS-791325 FOR TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE 4 INFECTION

✍ Hassanein, T.; Sims, K.; Bennett, M.; Gitlin, N.; Lawitz, E.; Nguyen, T.; Webste 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 60 KB

P1300 EFFICACY AND SAFETY OF DACLATASVIR

P1300 EFFICACY AND SAFETY OF DACLATASVIR IN COMBINATION WITH ASUNAPREVIR (DCV+ASV) IN CIRRHOTIC AND NON-CIRRHOTIC PATIENTS WITH HCV GENOTYPE 1B: RESULTS OF THE HALLMARK DUAL STUDY

✍ Kao, J.-H.; Heo, J.; Yoffe, B.; Sievert, W.; Jacobson, I.; Bessone, F.; Peng, C. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 129 KB

14 DUAL ORAL THERAPY WITH THE NS5A INHIB

14 DUAL ORAL THERAPY WITH THE NS5A INHIBITOR DACLATASVIR (BMS-790052) AND NS3 PROTEASE INHIBITOR ASUNAPREVIR (BMS-650032) IN HCV GENOTYPE 1B-INFECTED NULL RESPONDERS OR INELIGIBLE/INTOLERANT TO PEGINTERFERON/RIBAVIRIN

✍ F. Suzuki; K. Ikeda; J. Toyota; Y. Karino; T. Ohmura; K. Chayama; S. Takahashi; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 117 KB

Dual therapy with the nonstructural prot

Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders

✍ Kazuaki Chayama; Shoichi Takahashi; Joji Toyota; Yoshiyasu Karino; Kenji Ikeda; 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 905 KB

The following corrections have since been made: ''BMS-790052'' has been replaced throughout with ''daclatasvir''; ''BMS-50032'' has been replaced throughout with ''asunaprevir''. The article has been updated online and in print.